Assessment of new cardiovascular drugs: Relationships between considerations, professional characteristics, and prescribing

International Journal of Technology Assessment in Health Care

Volumn 17, Issue 4, 2001, Pages 559-570

  Wieringa, Nicolien F ^a   Denig, Petra ^a   De Graeff, Pieter A ^a   Vos, Rein ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiovascular drugs; Case study; Diffusion of innovation; Professional practice; Qualitative evaluation

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN POTASSIUM; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HOSPITAL PHARMACY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; PATIENT SATISFACTION; PHARMACIST; PHYSICIAN; PRESCRIPTION; PROFESSIONAL PRACTICE; SIDE EFFECT;

EID: 0035204220     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0266462301107105     Document Type: Article

References (26)

1. A study of general practitioners' reasons for changing their prescribing behavior
2. Atorvastatine
3. Decision to adopt new medical technology: A case study of thrombolytic therapy
4. Uneasy alliance - Clinical investigators and the pharmaceutical industry
5. Assimilating new therapeutic interventions into clinical practice: How does hypertension compare with other therapeutic areas?
6. Impact of clinical trials on the adoption of new drugs within a university hospital
7. Qualitative methods for assessing health care
8. Are me-too drugs justified?
9. Health technology assessment and clinical decision making: What is the best evidence?
10. Atorvastatin, turbostatin or OMO-power?
11. The rational use of therapeutic drugs in the 21st century
12. Losartan - A new antihypertensive
13. When to use a new drug
14. Implementing clinical practice guidelines: Social influence strategies and practitioner behavior change
15. Patterns of preference for information sources in the adoption of new drugs by specialists
16. Innovation in high risk drug therapy
17. Diffusion of new drugs in Danish general practice
18. Change in the established prescribing habits of general practitioners: An analysis of initial prescriptions in general practice
19. Local opinion leaders to improve health professional practice and health care outcomes (Cochrane Review)
20. Physicians and the pharmaceutical industry. Is a gift ever just a gift?
21. Cardiovascular drugs: Discrepancies in demographics between pre- and post-marketing use
22. Co-morbidity of "clinical trial" versus "real-world" patients using cardiovascular drugs
23. Losartan ACE voorbij?